Theratechnologies Resumes Distribution of EGRIFTA SV®

Core Insights - Theratechnologies Inc. has resumed distribution of EGRIFTA SV (tesamorelin for injection) after receiving approval from the U.S. FDA for two recently manufactured batches, with immediate shipment to pharmacies [1][2] - The company emphasizes its commitment to providing EGRIFTA SV to individuals with HIV and appreciates the FDA's collaboration in this process [2] - The FDA's review of the Company's Prior Approval Supplement is ongoing, with an action goal date set for April 18, 2025 [2] Company Overview - Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies aimed at redefining standards of care [3] - The company is publicly traded on both the TSX and NASDAQ under the ticker symbols TH and THTX, respectively [3]